Oxford BioMedica plc New era for cell and gene therapies – DirectorsTalk Interviews
|
Oxford BioMedica plc New era for cell and gene therapies
DirectorsTalk Interviews Advanced therapies: In only a week, gene therapies and gene-modified cell therapies have entered the global limelight: the first approval of a CAR-T therapy; Gilead's $12bn acquisition of US CAR-T biotech Kite Pharma; and the UK government's … |
